Wednesday, 03 February 2021 08:00 AM
Company Update
DURHAM, NC / ACCESSWIRE / February 3, 2021 / GeneCentric Therapeutics, a company making precision medicine more precise, announced today the appointment of Philippe Chemla, PhD, MBA, as Chief Business Officer. Dr. Chemla has extensive experience across multiple areas of life sciences research and development, with a focus on strategic collaborations and business development.
"Philippe brings a strong track record of senior management and strategic partnership development within both biotech and pharma, as well as life science companies with biomarker discovery and diagnostic development capabilities," said Dr. Mike Milburn, President and CEO of GeneCentric Therapeutics. "I am thrilled to work with Philippe again as he joins the GeneCentric team."
In his role as Chief Business Officer, Dr. Chemla will lead the company's efforts to expand its strategic collaborations which range from early-stage biotech to multi-national pharmaceutical companies. He will also work with the senior management team to bring the company's expanding pipeline of RNA-based predictive response signatures and molecular diagnostics that were developed using its Tumor and Immune Micro-Environment (TIME) Explorer platform to market.
"I look forward to working with the GeneCentric team as we continue to grow the strategic collaborations with pharmaceutical, biotechnology and diagnostic partners," said Dr. Philippe Chemla. "This is an exciting era where GeneCentric's RNA-based approach to developing novel gene signatures and diagnostics is gaining increased traction within precision medicine."
Previously, Dr. Chemla served as President of Diabetic Health Inc., CEO at Clinical Sensors where he negotiated its acquisition, Chief Business Officer for the David H. Murdock Research Institute, Vice President of Business Development at Metabolon where he led strategic engagements, Director of Commercial Development at Diosynth Biotechnology, and Business Development and Research Director at Syngenta and Novartis (USA and Switzerland.)
Dr. Chemla holds a PhD in Chemistry from the Louis Pasteur University (France) and an MBA from the Duke University Fuqua School of Business.
About GeneCentric
GeneCentric Therapeutics, Inc., based in Research Triangle Park, NC, is an RNA-based genomic solutions provider. The company's technologies are designed to parse the complexity of tumor and immune biology using its T(I)ME Explorer platform to discover and develop signatures of responder populations to oncology therapeutics. GeneCentric is commercializing its technology through strategic collaborations with pharmaceutical, biotechnology and diagnostics companies in applications throughout pre-clinical testing, clinical drug development and commercialization lifecycle phases. GeneCentric has deep expertise across multiple tumor types including lung, head and neck, bladder, pancreatic, kidney, glioblastoma, melanoma and multiple myeloma. They have an expansive pipeline of RNA-based signatures to characterize therapeutic cancer targets such as PD(L)-1, PARP, FGFR2/3, and specific cytokines, as well as a growing antigen discovery platform. For more information, please visit www.genecentric.com.
Contact:
GeneCentric Therapeutics, Inc.
Joel R. Eisner, Ph.D.
Sr. Vice President - Clinical & Corporate Development
Email: [email protected]
SOURCE: GeneCentric Therapeutics, Inc.